kiniksa
announces
upcoming
rilonacept
analyst
day
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
pipeline
assets
designed
modulate
immunological
pathways
implicated
across
spectrum
diseases
today
announced
company
host
virtual
rilonacept
analyst
day
monday
september
eastern
daylight
time
event
feature
presentations
kiniksa
management
team
market
opportunity
rilonacept
recurrent
pericarditis
well
company
continued
commercial
preparations
launch
strategy
additionally
guest
speaker
paul
cremer
md
cardiovascular
medicine
cleveland
clinic
review
burden
recurrent
pericarditis
current
treatment
landscape
unmet
need
rilonacept
discovered
developed
regeneron
pharmaceuticals
regeneron
approved
food
drug
administration
fda
brand
name
treatment
periodic
syndromes
caps
kiniksa
licensed
rilonacept
regeneron
evaluation
diseases
believed
mediated
alpha
beta
including
recurrent
pericarditis
fda
granted
breakthrough
therapy
designation
rilonacept
recurrent
pericarditis
orphan
drug
designation
rilonacept
pericarditis
based
highly
statistically
significant
phase
data
recurrent
pericarditis
biologic
license
application
bla
caps
transfer
kiniksa
company
plans
submit
supplemental
biologic
license
application
sbla
recurrent
pericarditis
fda
year
upon
receipt
fda
approval
rilonacept
recurrent
pericarditis
kiniksa
assume
sales
distribution
rilonacept
approved
indications
united
states
evenly
split
profits
sales
regeneron
webcast
conference
call
information
kiniksa
host
webcast
conference
call
eastern
daylight
time
monday
september
presentation
accessible
link
well
investors
media
section
company
website
individuals
also
participate
dialing
canada
international
using
conference
id
number
archived
webcast
available
kiniksa
website
days
beginning
approximately
one
hour
conclusion
event
recurrent
pericarditis
recurrent
pericarditis
painful
debilitating
autoinflammatory
cardiovascular
disease
typically
presents
chest
pain
often
associated
changes
electrical
conduction
sometimes
buildup
fluid
around
heart
called
pericardial
effusion
patients
pericarditis
deemed
recurrent
additional
episode
period
weeks
chronic
symptoms
one
episode
last
longer
three
months
recurrent
pericarditis
symptoms
impair
qualify
life
limit
physical
activities
lead
frequent
emergency
department
visits
hospitalizations
currently
treatments
recurrent
pericarditis
rilonacept
license
agreement
regeneron
regeneron
granted
kiniksa
exclusive
license
develop
commercialize
rilonacept
worldwide
aside
israel
egypt
turkey
select
countries
middle
east
north
africa
united
states
japan
kiniksa
license
initially
indications
involving
local
administration
eye
ear
oncology
deficiency
receptor
antagonist
dira
caps
kiniksa
successful
receiving
marketing
approval
rilonacept
united
states
new
indication
scope
license
granted
kiniksa
automatically
expand
include
dira
caps
united
states
japan
kiniksa
assume
sales
distribution
rilonacept
additional
indications
outside
united
states
japan
kiniksa
license
indications
local
application
eye
ear
oncology
caps
dira
certain
periodic
fever
syndromes
kiniksa
made
upfront
payment
million
regeneron
obligated
make
regulatory
milestone
payments
million
aggregate
thereafter
kiniksa
regeneron
evenly
split
profits
sales
rilonacept
deducting
certain
commercialization
expenses
subject
specified
limits
rilonacept
rilonacept
weekly
recombinant
fusion
protein
blocks
rilonacept
discovered
developed
regeneron
approved
fda
brand
name
treatment
caps
specifically
familial
cold
autoinflammatory
syndrome
syndrome
rilonacept
treatment
dira
currently
pending
fda
approval
following
submission
sbla
june
rilonacept
recurrent
pericarditis
investigational
drug
fda
granted
breakthrough
therapy
designation
rilonacept
recurrent
pericarditis
orphan
drug
designation
rilonacept
pericarditis
important
information
rilonacept
injection
blockade
may
interfere
immune
response
infections
serious
infections
reported
patients
taking
arcalyst
arcalyst
discontinued
patient
develops
serious
infection
taking
arcalyst
tnf
inhibitors
recommended
may
increase
risk
serious
infections
patients
receive
live
vaccine
taking
arcalyst
recommended
prior
initiation
therapy
arcalyst
patients
receive
recommended
vaccinations
appropriate
including
pneumococcal
vaccine
inactivated
influenza
vaccine
initial
development
program
arcalyst
six
serious
adverse
reactions
reported
four
patients
mycobacterium
intracellular
infection
gastrointestinal
bleeding
colitis
sinusitis
bronchitis
streptococcus
pneumoniae
meningitis
commonly
reported
adverse
reactions
associated
arcalyst
injection
site
reaction
upper
respiratory
tract
infection
patients
monitored
changes
lipid
profiles
provided
medical
treatment
warranted
treatment
immunosuppressants
including
arcalyst
may
result
increase
risk
malignancies
hypersensitivity
reactions
associated
arcalyst
administration
clinical
studies
rare
hypersensitivity
reaction
occurs
administration
arcalyst
discontinued
appropriate
therapy
initiated
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
implicated
across
spectrum
diseases
information
please
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
forwardlooking
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
expectation
respect
bla
caps
transferring
kiniksa
timing
submitting
sbla
fda
potential
clinical
stage
product
candidates
offer
differentiation
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
potential
impact
pandemic
measures
taken
response
pandemic
changes
operating
plan
funding
requirements
existing
new
competition
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
reports
subsequently
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
registered
trademark
regeneron
pharmaceuticals
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
